{"url_path":"/sec/plx/10-k/2026/item-14","section_key":"item-14","section_title":"Item 14 Principal Accountant Fees and Services","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-18","source_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029858-index.html","accession_number":"0001104659-26-029858","cik":"0001006281","ticker":"PLX","issuer_name":"Protalix BioTherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029858-index.html","primary_entity_key":"0001006281","primary_entity_name":"Protalix BioTherapeutics, Inc."},"word_count":66,"has_tables":true,"body_markdown":"Item 14.        Principal Accountant Fees and Services\n\nOur independent registered public accounting firm is[Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited,](plx-20251231xex23d1.htm)Tel Aviv, Israel, PCAOB ID. No. 1309.\n\nThe information appearing in our 2026 Proxy Statement under the heading “Ratification of Appointment of Independent Registered Public Accounting Firm” is incorporated by reference in this section.\n\n​\n\n73\n\n[Table of Contents](#TOC)\n\nPART IV"}